Literature DB >> 33862108

Piperlongumine inhibits the progression of osteosarcoma by downregulating the SOCS3/JAK2/STAT3 pathway via miR-30d-5p.

Yawei Hu1, Xinle Luo1, Jianhua Zhou1, Shaochu Chen1, Ming Gong1, Yue Deng1, Hao Zhang2.   

Abstract

AIMS: The present study evaluated the functions of Piperlongumine (PL) in osteosarcoma (OS) cell growth and metastasis both in vitro and in vivo. MAIN
METHODS: MTT assay was conducted to test the cytotoxic effects of PL on the human osteoblasts line HFOB1.19 and the human normal chondrocyte line C28/I2T. FITC-Annexin V and propidium iodide (PI) were used to examine cell apoptosis. The migration, invasion and relative epithelial-mesenchymal transition were examined by Transwell assay and Western blotting. Reverse transcription-quantitative PCR (RT-qPCR) was performed to analyze the cytokine signaling 3 (SOCS3) mRNA expression. TargetScan database was used to predict the target of SOCS3. The binding association between miR-30d-5p and SOCS3 in U2OS and MG63 cells was evaluated by the dual-luciferase reporter assay. A xenograft model was constructed to evaluate the effect of PL on OS cell growth in vivo. KEY
FINDINGS: The results revealed that PL inhibited the growth, migration, invasion, epithelial-mesenchymal transition, and promoted the apoptosis of OS cells dose-dependently. In addition, PL upregulated the protein levels of suppressor of SOCS3, while it inactivated the JAK2/STAT3 pathway, which was accompanied by a decreased level of microRNA (miR)-30d-5p. Furthermore, SOCS3was confirmed as a novel target of miR-30d-5p. Overexpression of miR-30d-5p not only led to decreased expression of SOCS3, but also dampened the antitumor effect of PL on OS. SIGNIFICANCE: The present data demonstrated that PL inhibited the progression of OS via downregulation of the SOCS3-mediated JAK2/STAT3 pathway by inhibiting miR-30d-5p.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  JAK2/STAT3; Osteosarcoma; Piperlongumine; Suppressor of cytokine signaling 3; microRNA-30d-5p

Year:  2021        PMID: 33862108     DOI: 10.1016/j.lfs.2021.119501

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  LINC00893 inhibits the progression of prostate cancer through miR-3173-5p/SOCS3/JAK2/STAT3 pathway.

Authors:  Chuigong Yu; Yu Fan; Yu Zhang; Lupeng Liu; Gang Guo
Journal:  Cancer Cell Int       Date:  2022-07-10       Impact factor: 6.429

Review 2.  miR-30d-5p: A Non-Coding RNA With Potential Diagnostic, Prognostic and Therapeutic Applications.

Authors:  Qinlu Zhao; Xin Yuan; Lian Zheng; Miaomiao Xue
Journal:  Front Cell Dev Biol       Date:  2022-01-27

3.  Discovery and validation of circulating miRNAs for the clinical prognosis of severe dengue.

Authors:  Umaporn Limothai; Nattawat Jantarangsi; Natthasit Suphavejkornkij; Sasipha Tachaboon; Janejira Dinhuzen; Watchadaporn Chaisuriyong; Supachoke Trongkamolchai; Mananya Wanpaisitkul; Chatchai Chulapornsiri; Anongrat Tiawilai; Thawat Tiawilai; Terapong Tantawichien; Usa Thisyakorn; Nattachai Srisawat
Journal:  PLoS Negl Trop Dis       Date:  2022-10-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.